Bortirel 3.5 mg Injection

Bortirel 3.5 mg Injection contains bortezomib 3.5 mg, a proteasome inhibitor used as an anticancer medicine. It is used in the treatment of multiple myeloma and mantle cell lymphoma. The medicine is administered by a healthcare professional through intravenous or subcutaneous injection.

BUY NOW

Bortezomib works by reversibly inhibiting the 26S proteasome, disrupting protein processing and promoting the death of certain cancer cells. Bortirel is used in specific treatment regimens for previously treated or newly diagnosed multiple myeloma and relapsed or refractory mantle cell lymphoma. The 3.5 mg strength is supplied as a powder for solution for injection and can be prepared for intravenous or subcutaneous administration. Bortirel is manufactured by Reliance Life Sciences and is available in 1 mg, 2 mg, and 3.5 mg strengths.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 3.5 mg
Dosage Form Powder for Solution for Injection
Route of Administration Intravenous / Subcutaneous
Pack Size 1 vial
Manufacturer Reliance Life Sciences

Product Also Known As

Bortirel 3.5 mg Injection, Bortirel 3.5 mg Vial, Bortirel 3.5 Injection, Bortirel Bortezomib Injection, Bortezomib 3.5 mg Injection, Bortezomib 3.5 mg Vial